Biogen Pharmachem Intrinsic Value
Biogen Pharmachem (BIOGEN) median intrinsic value is ₹0.68 from 3 valuation models (range ₹0–₹1), vs current price ₹0.27 — +151.9% upside (Trading Below Calculated Value), margin of safety 60.3%. Check BIOGEN company valuation to track the company's total market size over time.
BIOGEN Valuation Methods Summary — DCF, Graham Number & P/E
Biogen Pharmachem intrinsic value across 3 models vs current price ₹0.27 — upside/downside and value range per method. For current market price and key ratios, visit Biogen Pharmachem share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹0.68 | ₹0.61 - ₹0.75 | +151.9% | Book Value/Share: ₹11.00, P/B: 0.8x |
| Revenue Multiple Method | revenue | ₹0.11 | ₹0.10 - ₹0.12 | -59.3% | Revenue/Share: ₹0.11, P/S: 1.0x |
| Simple DCF (5Y) | dcf | ₹0.68 | ₹0.54 - ₹0.82 | +151.9% | CF Growth: 15.0%, Discount: 15% |
BIOGEN Intrinsic Value vs Market Price — All Valuation Models
Biogen Pharmachem fair value range ₹0–₹1 vs current market price ₹0.27 across 3 valuation models. See BIOGEN P/B ratio history to compare market price against book value per share.
BIOGEN Intrinsic Value Analysis — Undervalued or Overvalued?
Biogen Pharmachem median intrinsic value ₹0.68, current price ₹0.27 — Trading Below Calculated Value by 151.9%, margin of safety 60.3%.
What is the intrinsic value of BIOGEN?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Biogen Pharmachem (BIOGEN) is ₹0.68 (median value). With the current market price of ₹0.27, this represents a +151.9% variance from our estimated fair value.
The valuation range spans from ₹0.11 to ₹0.68, indicating ₹0.11 - ₹0.68.
Is BIOGEN undervalued or overvalued?
Based on our multi-method analysis, Biogen Pharmachem (BIOGEN) appears to be trading below calculated value by approximately 151.9%.
BIOGEN Financial Health — Key Ratios vs Industry Benchmarks
Biogen Pharmachem financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Asset Turnover Ratio | 0.01x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
BIOGEN Cash Flow Quality — Operating & Free Cash Flow
Biogen Pharmachem operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹2 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹-1 Cr | ₹-18 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |